Drug Trial Radar · NCT05865743
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
854
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Radboud University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development; Universitaire Ziekenhuizen KU Leuven
- First posted
- May 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary aim of the PERSuaDER-trial is to evaluate the effect of SDD on infectious complications after esophagectomy, focussed on the prevention of pneumonia
Conditions
- Esophageal Cancer
Interventions
SDDDrug
The intervention group receives SDD treatment additional to standard care, comprising two distinct liquids for oral administration: first the 5 ml amphotericin B suspension (100 mg/ml) and subsequently the 5 ml "SDD base for suspension", containing both colistin sulphate (20 mg/ml) and tobramycin sulphate (16 mg/ml). Patients take the 5 ml amphotericin B, followed by the 5 ml "SDD base for suspension", four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the cumulative incidence of postoperative pneumonia within 30 days after surgeryTime frame: Within 30 days after surgery
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
UZ Leuven
Leuven, Belgium · Recruiting
Radboudumc
Nijmegen, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.